Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 5, 2013, Pages 1087-1097

  Cassol, Edana ^a   Misra, Vikas ^a   Morgello, Susan ^b   Gabuzda, Dana ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

HCV; HIV; HIV associated neurocognitive disorders; IL 6; Inflammatory biomarkers; Innate immune activation; Interferon

Indexed keywords

ALPHA2B INTERFERON; BIOLOGICAL MARKER; CD14 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; RANTES;

AGING; ANTIVIRAL THERAPY; BODY MASS; COMORBIDITY; HEPATITIS C; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; METABOLISM; MIXED INFECTION; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STUDY DESIGN; SUBSTANCE ABUSE;

ADULT; AIDS DEMENTIA COMPLEX; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 84891371347     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9512-2     Document Type: Review

References (90)

1. The Mind Exchange Working Group (2013) Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 56:1004-1017
2. Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE, Buxton RB, Benson D, Smith DM, Little SJ, Richman DD, Moore DJ, Ellis RJ (2009) Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 73:702-708
3. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D (2008) Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3:e2516
4. Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214:231-241
5. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L (2006) The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 184:342-347
6. Berman JW et al (2006) NeuroAIDS, drug abuse, and inflammation: building collaborative research activities. J Neuroimmune Pharmacol 1:351-399
7. Boasso A, Shearer GM (2008) Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 126:235-242
8. Borjabad A, Morgello S, Chao W, Kim SY, Brooks AI, Murray J, Potash MJ, Volsky DJ (2011) Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog 7:e1002213
9. Brew BJ, Letendre SL (2008) Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry 20:73-88
10. Brew BJ, Pemberton L, Cunningham P, Law MG (1997) Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 175:963-966
11. Brown TT, Glesby MJ (2012) Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 8:11-21
12. Bruunsgaard H, Pedersen BK (2003) Age-related inflammatory cytokines and disease. Immunol Allergy Clin N Am 23:15-39
13. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC (2013) Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 27(9):1387-1395
14. Byrd DA, Robinson-Papp J, Mindt MR, Mintz L, Elliott K, Lighty Q, Morgello S (2013) Isolating cognitive and neurologic HIV effects in substance-dependent, confounded cohorts: a pilot study. J Int Neuropsychol Soc 19:463-473
15. Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17(Suppl 1):S141-S148
16. Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D (2013) Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 13:203
17. Clark KH, Wiley CA, Bradberry CW (2013) Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 23:174-188
18. Cohen RA, de la Monte S, Gongvatana A, Ombao H, Gonzalez B, Devlin KN, Navia B, Tashima KT (2011) Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning. J Neuroimmunol 233:204-210
19. Cotler SJ, Craft T, Ferris M, Morrisey M, McCone J, Reddy KR, Conrad A, Jensen DM, Albrecht J, Taylor MW (2002) Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. J Interferon Cytokine Res 22:549-554
20. Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, Weintrob A, Barthel RV, Fraser S, Agan BK (2010) Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 5:e10106
21. d'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, Vullo V (2011) HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retrovir 27:355-364
22. del Palacio M, Alvarez S, Munoz-Fernandez MA (2012) HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol 22:33-45
23. Devlin KN, Gongvatana A, Clark US, Chasman JD, Westbrook ML, Tashima KT, Navia B, Cohen RA (2012) Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc 18:68-78
24. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M (2007) Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 196:1779-1783
25. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA (1997) Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 42:679-688
26. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747-1751
27. Enting RH, Foudraine NA, Lange JM, Jurriaans S, van der Poll T, Weverling GJ, Portegies P (2000) Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol 102:216-221
28. Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, Moore D, Ellis R, Cherner M, Gelman B, Morgello S, Singer E, Grant I, Masliah E (2009) Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 15:360-370
29. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128:92-105
30. Fritz-French C, Tyor W (2012) Interferon-alpha (IFNalpha) neurotoxicity. Cytokine Growth Factor Rev 23:7-14
31. Gan X, Zhang L, Newton T, Chang SL, Ling W, Kermani V, Berger O, Graves MC, Fiala M (1998) Cocaine infusion increases interferon-gamma and decreases interleukin-10 in cocaine-dependent subjects. Clin Immunol Immunopathol 89:181-190
32. Gartner S, Liu Y (2002) Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol 8:69-75
33. Gelman BB, Lisinicchia JG, Morgello S, Masliah E, Commins D, Achim CL, Fox HS, Kolson DL, Grant I, Singer E, Yiannoutsos CT, Sherman S, Gensler G, Moore DJ, Chen T, Soukup VM (2012a) Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr
34. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, Masliah E, Commins DL, Brandt D, Grant I, Singer EJ, Levine AJ, Miller J, Winkler JM, Fox HS, Luxon BA, Morgello S (2012b) The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One 7:e46178
35. Gisolf EH, van Praag RM, Jurriaans S, Portegies P, Goudsmit J, Danner SA, Lange JM, Prins JM (2000) Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 25:426-433
36. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5:69-81
37. Goodkin K, Wilkie FL, Concha M, Hinkin CH, Symes S, Baldewicz TT, Asthana D, Fujimura RK, Lee D, van Zuilen MH, Khamis I, Shapshak P, Eisdorfer C (2001) Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol 54(Suppl 1):S35-S43
38. Gras G, Kaul M (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7:30
39. Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, Harding CV (2013) Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 8:e56527
40. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25:625-633
41. Heaton RK et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-16
42. Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ (2008) Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis 27:11-17
43. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860-867
44. Justice AC (2010) HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 7:69-76
45. Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, Gabuzda D (2012a) Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 60:234-243
46. Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, Morgello S, Gabuzda D (2012b) A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 7:e30881
47. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA (2005) HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12(Suppl 1):878-892
48. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5:e203
49. Leeansyah E, Malone DF, Anthony DD, Sandberg JK (2013) Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 8:117-124
50. Lehmann C, Taubert D, Jung N, Fatkenheuer G, van Lunzen J, Hartmann P, Romerio F (2009) Preferential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients. AIDS Res Hum Retrovir 25:577-581
51. Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45-55
52. Letendre SL, Cherner M, Ellis RJ, Marquie-Beck J, Gragg B, Marcotte T, Heaton RK, McCutchan JA, Grant I (2005) The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 19(Suppl 3):S72-S78
53. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121:2111-2117
54. Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, Morgello S, Gabuzda D (2011) Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 57:371-379
55. Martin-Thormeyer EM, Paul RH (2009) Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 19:215-231
56. Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1:182-188
57. McArthur JC, Brew BJ (2010) HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 24:1367-1370
58. McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699-714
59. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, Lanier ER (1997) Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 42:689-698
60. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM, Grant I (2012) Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 78:485-492
61. Morgello S (2005) The nervous system and hepatitis C virus. Semin Liver Dis 25:118-121
62. Morgello S, Estanislao L, Ryan E, Gerits P, Simpson D, Verma S, DiRocco A, Sharp V (2005) Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 19(Suppl 3):S116-S122
63. Naylor S (2003) Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 3:525-529
64. Operskalski EA, Kovacs A (2011) HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 8:12-22
65. Ortiz AM, Silvestri G (2009) Immunopathogenesis of AIDS. Curr Infect Dis Rep 11:239-245
66. Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried MW, Robertson KR (2006) Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 20:1591-1595
67. Pedersen KK, Pedersen M, Gaardbo JC, Ronit A, Hartling HJ, Bruunsgaard H, Gerstoft J, Ullum H, Nielsen SD (2013) Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr
68. Pulliam L, Rempel H, Sun B, Abadjian L, Calosing C, Meyerhoff DJ (2011) A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations. AIDS 25:1721-1726
69. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L (2010) Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 24:1415-1423
70. Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L (2013) Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS One 8:e55776
71. Rios-Olivares E, Vila LM, Reyes JC, Rodriguez JW, Colon JH, Pagan NO, Marrero A, Rios-Orraca ZM, Boukli NM, Shapshak P, Robles RR (2006) Impaired cytokine production and suppressed lymphocyte proliferation activity in HCV-infected cocaine and heroin ("speedball") users. Drug Alcohol Depend 85:236-243
72. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18:388-399
73. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN (2009) Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 200:973-983
74. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P (2004) Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62:957-962
75. Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, Anderson J, Ratanasuwan W, Gendelman HE, Swindells S (2001) Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 184:699-706
76. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142
77. Sandler NG, Douek DC (2012) Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 10:655-666
78. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203:780-790
79. Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J, Tyor WR (2009) Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci 29:3948-3955
80. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P (2011) HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25:561-575
81. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM (2010) Aging of the innate immune system. Curr Opin Immunol 22:507-513
82. Sun B, Abadjian L, Rempel H, Monto A, Pulliam L (2013) Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr 62:190-196
83. Taylor LE, Swan T, Mayer KH (2012) HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 55(Suppl 1):S33-S42
84. Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA (1993) Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 150:4687-4692
85. Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulianelli M, Ippolito G, Antinori A, Narciso P (2005) Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 11:265-273
86. Vallejo R, de Leon-Casasola O, Benyamin R (2004) Opioid therapy and immunosuppression: a review. Am J Ther 11:354-365
87. Wendelken LA, Valcour V (2012) Impact of HIV and aging on neuropsychological function. J Neurovirol 18:256-263
88. Wolfe D, Carrieri MP, Shepard D (2010) Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376:355-366
89. Wright PW, Heaps JM, Shimony JS, Thomas JB, Ances BM (2012) The effects of HIV and combination antiretroviral therapy on white matter integrity. AIDS 26:1501-1508
90. Yamamoto BK, Moszczynska A, Gudelsky GA (2010) Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 1187:101-121